title: Report of the 2014 Cent Gardes HIV Vaccine Conference-Part 2: Cell-mediated immunity, mucosal protection, and clinical trials: Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October, 2014.
abstract: The 2014 Cent Gardes Conference took place on October 5-7, 2014, at the Fondation Mérieux Conference Center, on the shores of the Annecy Lake and aimed to review the progress and promise of HIV vaccines. The elicitation of broadly neutralizing antibodies (bNAbs), their use in passive immunization, as well as their genetic delivery (vector immunoprophylaxis) by a recombinant Adenovirus-associated virus (AAV) vector were reviewed in a preceding article [1]. Approaches to the elicitation of long-lasting T cell or mucosal immunity were also discussed and are now reviewed here. The possibility of eliciting mucosal IgAs was discussed, since it was demonstrated that transcytosis-blocking IgAs can protect monkeys against repeated vaginal challenge with a pathogenic chimeric simian and human immunodeficiency virus (SHIV). The possibility of purging the HIV reservoirs from HIV-infected persons and developing a cure of the disease was also discussed.
authors.affiliation: French National Academy of Medicine, 16 rue Bonaparte, 75006 Paris, France. Electronic address: Marc.girard36@wanadoo.fr.
authors.forename: Marc P
authors.initials: MP
authors.lastname: Girard
authors.affiliation: Fondation Mérieux, 17 rue Bourgelat, 69002 Lyon, France. Electronic address: Valentina.picot@fondation-merieux.org.
authors.forename: Valentina
authors.initials: V
authors.lastname: Picot
authors.affiliation: Fondation Mérieux, 17 rue Bourgelat, 69002 Lyon, France. Electronic address: Christophe.longuet@fondation-merieux.org.
authors.forename: Christophe
authors.initials: C
authors.lastname: Longuet
authors.affiliation: Sanofi, 640 Memorial Drive, Cambridge, MA 021139, United States. Electronic address: Gary.nabel@sanofi.com.
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D005602:France; D006678:HIV / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D007111:Immunity, Cellular; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D007071:Immunoglobulin A, Secretory
keywords: Cellular immunity; Fc receptor; HIV-1; Immunoglobulin A; Latent proviruses; Live vectored vaccines; Mucosal immunity; T lymphocytes